SCHEMBL29598261

SCHEMBL29598261

C=C1C(=O)N[C@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(=O)O)[C@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](/C=C/C(C)=C/[C@H](C)[C@H](Cc2ccccc2)OC)[C@H](C)C(=O)N[C@@H](C(=O)O)CCC(=O)N1C

nearest known ligand 0.89

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.89
TFPI2 P48307 2/20 0.89
NPY4R P50391 2/20 0.89
PPP5C P53041 2/20 0.89
PPM1A P35813 1/20 0.89
PPP1CC P36873 1/20 0.89
PPP2R2A P63151 1/20 0.89
PPP2R5A Q15172 1/20 0.89
SLCO1B3 Q9NPD5 3/20 0.87
SLCO1B1 Q9Y6L6 3/20 0.87
PPM1B O75688 1/20 0.76
KLK7 P49862 2/20 0.34
MC4R P32245 2/20 0.33
MC3R P41968 2/20 0.33
MEN1 O00255 3/20 0.33
MC5R P33032 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29711569 0.96 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL29350595 0.96 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL29777431 0.96 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL31005304 0.96 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL29350648 0.96 PTPN1 (0.95) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL30788333 0.95 SLCO1B3 (0.96) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL30788332 0.95 SLCO1B3 (0.96) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL38650007 0.95 SLCO1B3 (0.96) PTPN1TFPI2NPY4RPPP5CPPM1A
Microcystin-Lr SCHEMBL29349513 0.94 PTPN1 (1.00) PTPN1TFPI2NPY4RPPP5CPPM1A
SCHEMBL29897131 0.94 PTPN1 (1.00) PTPN1TFPI2NPY4RPPP5CPPM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115201265-B Method for detecting proportion of resin and curing agent in composite material and curing degree 中国民用航空飞行学院 2024-09-17 CN claimed
CN-114569918-A Method and device for controlling charging amount and effective amount of fire extinguishing agent of lithium battery fire extinguishing system 中国电力科学研究院有限公司 2022-06-03 CN claimed
US-20250025480-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION UNIVERSITÉ PARIS CITÉ (FR) 2025-01-23 US disclosed
EP-4367970-A4 METHOD AND APPARATUS FOR HANDLING USER PLANE IN WIRELESS COMMUNICATION SYSTEM SUPPORTING MR-MC Samsung Electronics Co., Ltd. (KR) 2025-01-22 EP disclosed
CN-115201265-B Method for detecting proportion of resin and curing agent in composite material and curing degree 中国民用航空飞行学院 2024-09-17 CN disclosed
EP-4367970-A1 METHOD AND APPARATUS FOR HANDLING USER PLANE IN WIRELESS COMMUNICATION SYSTEM SUPPORTING MR-MC Samsung Electronics Co., Ltd. (KR) 2024-05-15 EP disclosed
EP-4367970-A1 METHOD AND APPARATUS FOR HANDLING USER PLANE IN WIRELESS COMMUNICATION SYSTEM SUPPORTING MR-MC Samsung Electronics Co., Ltd. (KR) 2024-05-15 EP disclosed
WO-2023153801-A1 METHOD AND APPARATUS FOR HANDLING USER PLANE IN WIRELESS COMMUNICATION SYSTEM SUPPORTING MR-MC SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-08-17 WO disclosed
WO-2023153801-A1 METHOD AND APPARATUS FOR HANDLING USER PLANE IN WIRELESS COMMUNICATION SYSTEM SUPPORTING MR-MC SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-08-17 WO disclosed
US-20230097413-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) 2023-03-30 US disclosed
US-20220291234-A1 A METHOD FOR DIAGNOSING OR MONITORING KIDNEY FUNCTION OR DIAGNOSING KIDNEY DYSFUNCTION IN PEDIATRIC PATIENTS SPHINGOTEC GMBH (DE) 2022-09-15 US disclosed
CN-114569918-A Method and device for controlling charging amount and effective amount of fire extinguishing agent of lithium battery fire extinguishing system 中国电力科学研究院有限公司 2022-06-03 CN disclosed
CN-114364984-A A method of diagnosing or monitoring renal function or diagnosing renal dysfunction in a pediatric patient 思芬构技术有限公司 2022-04-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230097413-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION ADCYAP1R1, MC2R, NR3C2 PTPN1 2625/4885TFPI2 1713/4885NPY4R 800/4885
US-20250025480-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHOROIDAL NEOVASCULARISATION VEGFA, NR3C2, ADCYAP1R1 PTPN1 3979/4885TFPI2 841/4885NPY4R 1010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.